covidvaccines corona-210821171459 (1).pdf

Covid vaccines

1. COVID-19 VACCINE
THE GOOD NEWS
Dr. IMMANUEL JOSHUA
Junior Resident,
Department of Community Medicine,
Institute of Medical Sciences,
Banaras Hindu University,
Varanasi-221 005.
Email: [email protected]

2. What is a vaccine and how does it work?
•Vaccinespreventdiseasesthatcanbedangerous,or
evendeadly.Theyworkwithyourbody’snatural
defensestosafelydevelopprotectionfromadisease.
•Avaccinehelpsyourimmunesystemtoproduce
antibodies.Aftergettingvaccinated,youhave
protectionfromthatdisease,withouthavingtogetthe
diseasefirst.
•Unlikemostmedicines,whichtreatorcurediseases,
vaccinespreventthem.

3. Types of Vaccine

4. Pipeline Highlights
The UK, Bahrain, Canada,
Kuwait and Mexico
granted emergency use
authorization to the
Pfizer-BioNTechvaccine,
with Saudi Arabia
granting full approval. On
December 11th, the FDA
approved the vaccine for
emergency use in the US
and inoculations are set
to begin within days. The
vaccine is also pending
regulatory review in
INDIA.
UAE & Bahrain approved
Sinopharm/Beijing
Institute of Biological
Products inactivated
vaccine • Sanofi-GSK
vaccine delayed till late
2021 after early-phase
data revealed reduced
immunogenicity in older
adults • Clinical
development of
University of Queensland
candidate abandoned
following false-positive
HIV results in some
participants
Full results published on
December 8th in the
Lancet reveal that
AstraZeneca and
University of Oxford’s
vaccine is safe and 70%
effective in preventing
infection, with efficacy
ranging from 62% to 90%
based on dose. The
Serum Institute has
applied for emergency
use authorization of the
AZD1222 vaccine in
INDIA
Modernaapplied to the
FDA and the European
Medicines Agency for
emergency authorization
of its coronavirus vaccine
on November 30th and
December 1st,
respectively. The
company will also begin
testing its vaccine in 12 to
17-year-olds this month
in a 3000-person phase
2/3 trial in the US.

5. Pipeline Diversity
COVID VACCINE

6. Race to Efficacy Data
Experts estimate that in each trial, ~150 infections will be required to demonstrate 60% efficacy with statistical
significance. Speed of enrollment and rate of infection will determine when efficacy data will be available

7. COVISHIELD
India approved the Emergency Authorisation against
novel coronavirus —Covishieldby Serum Institute of India
Serum Institute of India, the world's largest vaccine
manufacturer by volume, joined hands with British-Swedish
drugmakerto produce 1 billion doses of its COVID-19 vaccine.
The first 100 million doses of Covishieldwere being sold to
the Indian government at a special price of ₹200
The local version of Oxford-AstraZeneca COVID-19
vaccine will be known as COVISHIELD

8. Indigenous vaccine
India's indigenous COVID-19 vaccine by Bharat Biotech is
developed in collaboration with ICMR-(NIV).
COVAXIN
After successful completion of the interim analysis, Bharat Biotech
received DCGI approval for Phase 3 clinical trials in 26,000
participants in over 25 centres across India.
“Based on the feedback from the dry-run of vaccination drive, the
health ministry is ready to introduce Covid-19 vaccine within 10
days from the date of emergency use authorisation,”

9. VACCINE PLATFORM
DESCRIPTION
Viral vector (Non-replicating) Inactivated virus
TYPE OF VACCINE ChAdOx1-S -(AZD1222)
Whole-VirionInactivated
SARS-CoV-2 Vaccine
(BBV152)
NUMBER OF DOSES 1-2 2
DOSING SCHEDULE Day 0 + 28 Day 0 + 14
ROUTE OF ADMINISTRATION IM IM
DEVELOPERS
AstraZeneca + University of
Oxford
Bharat Biotech International
Limited
MANUFACTURING COMPANY India +UK India
CLAIMED EFFICACY
62% in two full doses,90% of
those initially given half dose
60-70%
COVISHIELD COVAXIN

10. The Union Health Ministry said in a statement on Thursday that the decision
was based on “available real-life evidence particularly from the U.K..’’
No change in interval of Covaxinvaccine doses
Changes in Schedule

11. SputnikV-ThirdCovid-19vaccinetobe
approvedinIndia-willbeavailableinthecountryfromthe
secondweekofJuneaccordingtoApolloHospitalsGroup.
ExecutiveVice-chairpersonoftheApolloGroupofHospitals
talkedaboutadministeringabout20millionCovid-19
vaccinesbySeptember.
Asingle-dose Covid-19 vaccine -is up for approval in a few
weeks. It could be the first single-dose Covid-19 vaccine
approved in India.
SPUTNIK LIGHT

13. 98,27,025
1,53,39,068
6,35,32,5451,02,15,474
5,77,48,2351,84,69,925
67,47,730
84,19,860
1,51,52,040
1
st
DOSE 2
nd
DOSE
Health Care Workers
Frontline Workers
People aged 18-44years
People aged ≥45 years
People aged ≥60 years
COVID-19 VACCINATION COVERAGE
(As on 27/05/21)
TOTAL ACHIEVEMENT: 4,38,52,98915,15,98,913

14. Vaccine Coverage Trends
(INDIA)

16. Candidate gets another SMS and OTP & details of appointment for second dose
Candidate is vaccinated & Vaccination officer updates data on CoWINapp
Candidate’s details on CoWINapp verified & Verification using OTD received via SMS
Recipient has to wait for 30 minutes & to be observed for any allergic reaction
Vaccination officer scans identification document
Candidate reaches vaccination site and shows the SMS to vaccination officer
Candidate registers on CoWINapp and receives SMS with time and dateT
H
E
P
R
O
C
E
S
S

17. CovidVaccine Intelligence Network
CoWIN

18. Model
Portal

19. Do the COVID-19 vaccines have any side effects?
•Serioussideeffectsfromvaccines,includingtheCOVID-19vaccine,arerare.
•Sideeffectsarenormalsignsthatyourbodyisbuildingprotection.
•Themostcommonsideeffectsareminorandinclude:
oTiredness
oHeadache
oPainattheinjectionsite
oMuscleand/orjointpain
oChills
oNauseaand/orvomiting
oFever

20. What are the benefits of getting a COVID-19 vaccine?
•COVID-19 vaccination will help keep you from getting sick
from COVID-19.
•Wearing masks and social distancing help lower your chance of
getting the virus or spreading it to others, but these measures are
not enough.
•ThecombinationofgettingvaccinatedandfollowingGOI‘s
recommendationstoprotectyourselfandotherswillofferthe
bestprotectionfromCOVID-19.
•The more people who get vaccinated, the faster we can get back
to our normal lives.

21. Can I get COVID-19 from the COVID-19 vaccines?
No.The vaccines do not contain the live virus that causes COVID-19.
This means that you can’t catch COVID-19 from the vaccine.

22. Can a lactating mother get COVID-19 vaccine? YES
Instructions by WHO;

23. Vaccination saves lives, provides immunity and
protects us from contracting diseases
The vaccines have been developed and will be
introduced to the public after undergoing various
trials and safety protocols
It is critical for us to get the vaccine to protect
ourselves, our families, friends and communities from
the infection
Though it is true that the vaccines have been
developed in a short time frame, they have
undergone all necessary protocols

24. Adequate safety & efficacy tests have been done on
these vaccines & regulatory approval has been given
only after confirming all required checks
While administering the vaccine, all safety protocols
will be followed at the vaccination centers
All vaccinators have been adequately trained in
vaccine safety protocols
Even after vaccination, everyone needs to follow
COVID appropriate behaviour

25. Wear a mask or face cover
Practisefrequent hand washing or use
hand sanitization
Maintain 6 feet physical distance (Do GajDoori)
If any symptoms develop, promptly self-isolate
If any symptoms develop, seek medical assistance

26. Defining vaccine confidence
Vaccine confidence is the trust that patients, parents, or providers have in:
Recommended vaccines
Providers who administer vaccines
Processes and policies that lead to vaccine
development, licensure, manufacturing,
and recommendations for use

27. Willingness to accept a vaccine falls on a continuum

28. Strategies for building confidence in healthcare personnel
6. Make the decision to get vaccinated visible and celebrate it!
5. Talk to non-medical staff about the importance of getting vaccinated.
4. Provide information and resources to healthcare teams about COVID-19 vaccines, how they
are developed and monitored for safety, and how teams can talk to others about the vaccines.
3. Share key messages with staff through emails, breakroom posters, and other channels.
2. Host discussions where personnel at different levels can provide input and ask questions.
1. Encourage senior leaders to be vaccine champions.

29. CURRENT SCENARIO

30. THANK YOU